A once-weekly drug from MBX Biosciences achieved the primary goal of a mid-stage clinical trial for patients with chronic hypoparathyroidism, a type of hormonal disorder. The results reported Monday, however, were less impressive when compared to the benefits of an approved treatment.

In the 12-week study, the MBX drug, called canvuparatide, posted a 63% response rate compared to a placebo response of 31%. The treatment effect was statistically significant but narrower than hoped, due partly to a high placebo response rate.

The outcome may leave investors questioning the potential benefit of canvuparatide relative to Yorvipath, a competing medicine from Ascendis Pharma approved last year.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page